Biogen, Inc. head of R&D Alfred Sandrock’s surprise announcement that he will retire at the end of the year marks the second time Biogen has lost an R&D chief in the midst of aducanumab controversy. Sandrock is recognized as the driving force behind the Aduhelm approval, and took over from Michael Ehlers right before the unexpected regulatory filing of the Alzheimer’s drug based on mixed data.
Sandrock’s retirement will be just months after the launch of Aduhelm (aducanumab), which Sandrock shepherded through clinical development and advocated...
